Trial set for world’s first leprosy vaccine
Six of every ten persons infected with leprosy are from South-East Asia
Two US-based organisations have partnered to lead the vaccine project
The project has an edge due to identification and mapping of the bacteria genome
Leprosy is a chronic infection caused by the bacillus Mycobacterium leprae An infected person develops skin lesions and may lose eyesight and the ability to feel pain. While no vaccine has been developed yet to prevent the disease, it can be treated through multidrug therapy.
According to the WHO, at least 6 out of every 10 persons infected with leprosy come from South-East Asia. The Philippines and Indonesia are among the 18 countries worldwide that reported more than 1,000 new cases for 2011 alone.
The vaccine development project is led by the Infectious Disease Research Institute (IDRI), a non-profit organisation based in the United States focusing on neglected diseases in the developing world, and the American Leprosy Missions (ALM), a Christian group providing financial and technical support to people affected by leprosy. For the clinical testing phase, they have partnered with the Philippine-based Cebu Leprosy and Tuberculosis Research Foundation.
“All the experimental and animal data have been assembled to make the case that this product is worth taking forward to human trials,” ALM communications director Sarah Hesshaus tells SciDev.Net about the leprosy vaccine.
For the past 12 years, the ALM, in partnership with IDRI, has invested US$4 million into the endeavour to develop the vaccine and a new diagnostic test for leprosy. It has been an uphill battle since “the leprosy bacteria grow very slowly and have been notoriously difficult to grow in laboratories,” Hesshaus says.
Malcolm Duthie, a senior scientist at IDRI and head researcher for the project, further explains that the advancement of vaccines through various clinical trial phases can take significant periods of time as “safety and efficacy are of utmost importance”.
“The current transition of the leprosy vaccine from the preclinical to the clinical testing phase has necessitated a large amount of due diligence and care in manufacturing, which precludes initiation of safety trials in a small number of individuals,” Duthie explains.
Arturo Cunanan Jr, chief of the Culion Sanitarium and General Hospital in Palawan, Philippines, welcomes the potential breakthrough: “For the first time, the genome of the bacteria that cause leprosy has been identified and mapped.”
The IDRI-ALM study, he says, is a huge improvement over earlier studies such as the research of Jacinto Convit, a Venezuelan doctor and scientist. Convit combined a bacterium found in armadillos and existing tuberculosis treatment to produce an experimental vaccine against leprosy. But up to now, scientists all over the globe are still trying to perfect a vaccine that can eradicate the disease.
Cunanan says, currently, the most important aspect of leprosy treatment is early diagnosis, when the patient has no disability yet.
“So if scientists can develop a vaccine that can prevent people from developing the disease, that will have a great impact in overcoming the disability and its social stigma,” he notes.
This article has been produced by SciDev.Net's South-East Asia & Pacific desk.